OLEMA PHARMACEUTICALS INC (OLMA)
US68062P1066 - Common Stock
Commit To Purchase Olema Pharmaceuticals At $5, Earn 12% Annualized Using Options
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage...
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4...
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
Data published in Molecular Cancer Therapeutics describes the scientific background underlying the design, discovery and optimization of palazestrant...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage...
Noteworthy Friday Option Activity: OLMA, TGT, LAZ
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a biopharmaceutical company...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage...
Olema Pharmaceuticals files to sell 13.21M common shares for holders (NASDAQ:OLMA)
Olema Pharmaceuticals (OLMA) files prospectus for resale of 13.21M common shares by selling stockholders. Not an offer to sell securities.
Notable Wednesday Option Activity: AZZ, DCGO, OLMA
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer...
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Commit To Purchase Olema Pharmaceuticals At $10, Earn 29.5% Annualized Using Options
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage...
Olema stock falls after data for lead asset in breast cancer
Olema Pharmaceuticals (OLMA) announces interim results from a Phase 1b/2 clinical study for its breast cancer drug palazestrant. Read more here.
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage...
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data...
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.
The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO.
Olema Pharmaceuticals GAAP EPS of -$0.48 (NASDAQ:OLMA)
Olema Pharmaceuticals press release (NASDAQ:OLMA): Q3 GAAP EPS of -$0.48.Cash, cash equivalents and marketable securities position of $276.9 million as of...
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth...